Loading…
Makers Laboratories (MAKERSL)₹268.21+19.94%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Makers Laboratories reported sales of ₹42.72 Cr, up 22.2% from Jun 2025, and net profit of ₹4.60 Cr, up 253.8% year on year. For the year to Mar 2026, sales were ₹141 Cr and net profit ₹8.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.01 | 26.46 | 27.78 | 29.53 | 29.52 | 27.64 | 33.85 | 34.96 | 34.11 | 35.62 | 35.70 | 42.72 |
| Expenses | 24.88 | 26.35 | 26.99 | 27.81 | 27.39 | 26.41 | 30.83 | 32.05 | 31.94 | 31.54 | 30.52 | 35.88 |
| Operating Profit | 0.21 | 0.21 | 0.85 | 1.80 | 2.18 | 1.30 | 3.08 | 3.00 | 2.29 | 4.15 | 5.29 | 6.95 |
| OPM % | 0.8% | 0.8% | 3.1% | 6.1% | 7.4% | 4.7% | 9.1% | 8.6% | 6.7% | 11.7% | 14.8% | 16.3% |
| Other Income | 0.42 | 0.36 | 0.44 | −0.50 | 10.64 | 0.86 | 0.09 | 0.26 | 0.35 | 0.34 | 0.77 | 0.60 |
| Interest | 0.50 | 0.54 | 0.53 | 0.50 | 0.44 | 0.20 | 0.19 | 0.19 | 0.23 | 0.21 | 0.18 | 0.16 |
| Depreciation | 1.12 | 1.15 | 1.14 | 1.27 | 1.28 | 1.30 | 0.89 | 1.11 | 1.12 | 1.13 | 1.12 | 1.12 |
| Profit before tax | −1.02 | −1.13 | −0.39 | −0.48 | 11.11 | 0.69 | 2.12 | 1.99 | 1.30 | 3.16 | 4.75 | 6.30 |
| Tax % | 10.9% | −4.5% | 152.7% | 49.0% | 12.0% | 60.3% | 24.7% | 34.9% | 42.7% | 28.0% | 24.9% | 27.1% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | −1.14 | −1.07 | −0.98 | −0.71 | 9.78 | 0.28 | 1.59 | 1.30 | 0.75 | 2.28 | 3.57 | 4.60 |
| EPS (Rs) | −2.26 | −2.60 | −2.18 | −1.65 | 14.93 | −0.50 | −0.07 | 0.74 | −0.19 | 1.58 | 1.84 | 2.53 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 68.92 | 127 | 101 | 104 | 121 | 141 | 148 |
| Expenses | 60.10 | 108 | 98.16 | 103 | 112 | 126 | 130 |
| Operating Profit | 7.99 | 18.99 | 2.99 | 0.99 | 8.99 | 15.01 | 18.68 |
| OPM % | 12.0% | 15.0% | 3.3% | 1.1% | 7.0% | 11.0% | 12.6% |
| Other Income | 1.01 | 2.99 | 1.99 | 2.01 | 10.99 | 2.01 | 2.06 |
| Interest | 2.01 | 2.01 | 2.01 | 2.01 | 1.01 | 1.01 | 0.78 |
| Depreciation | 4.99 | 3.99 | 3.99 | 4.98 | 4.99 | 4.99 | 4.49 |
| Profit before tax | 3.01 | 16.02 | −1.01 | −4.01 | 13.02 | 11.02 | 15.51 |
| Tax % | 50.1% | 25.1% | 161.0% | 23.1% | 19.1% | 30.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 11.01 | 0.00 | 0.00 |
| Net Profit | 1.01 | 12.02 | −2.01 | −5.01 | 11.02 | 8.01 | 11.20 |
| EPS (Rs) | −0.55 | 8.43 | −8.04 | −10.60 | 12.68 | 3.97 | 5.76 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 5.01 | 5.01 | 6.01 | 6.01 | 6.01 | 6.01 |
| Reserves | 48.90 | 54.82 | 62.84 | 56.83 | 64.86 | 66.87 |
| Borrowings | 20.94 | 22.95 | 16.97 | 21.94 | 7.99 | 8.97 |
| Other Liabilities | 62.05 | 62.12 | 66.11 | 76.15 | 70.11 | 85.09 |
| Total Liabilities | 136 | 144 | 152 | 161 | 148 | 167 |
| Fixed Assets | 70.98 | 67.96 | 84.96 | 86.93 | 74.01 | 70.96 |
| CWIP | 0.00 | 8.98 | 0.00 | 0.00 | 0.99 | 3.99 |
| Investments | 1.99 | 0.00 | 0.00 | 3.01 | 0.00 | 12.01 |
| Other Assets | 62.93 | 65.96 | 66.97 | 70.99 | 72.97 | 80.98 |
| Inventories | 27.40 | 23.79 | 31.26 | 33.73 | 33.99 | 44.87 |
| Trade receivables | 16.64 | 13.57 | 19.90 | 19.91 | 28.08 | 19.90 |
| Cash & equivalents | 6.24 | 8.70 | 4.38 | 2.24 | 0.66 | 0.64 |
| Total Assets | 136 | 144 | 152 | 161 | 148 | 167 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 17.99 | −8.99 | 0.99 | −3.99 | 13.99 |
| Cash from investing activity | −22.08 | 1.01 | −7.02 | 20.07 | −15.04 |
| Cash from financing activity | 0.00 | 5.99 | 5.99 | −15.97 | 0.00 |
| Net cash flow | −2.99 | −1.99 | 0.00 | 0.00 | 0.00 |
| Capex | 9.85 | 12.87 | 6.59 | 3.92 | 3.70 |
| Free cash flow | 9.03 | −21.08 | −6.02 | 11.03 | 11.04 |
| CFO / OP % | 128.1% | −184.9% | 232.1% | −20.0% | 118.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 89 | 40 | 73 | 71 | 86 | 53 |
| Inventory days | 343 | 165 | 280 | 226 | 229 | 249 |
| Days payable | 183 | 39 | 92 | 113 | 80 | 111 |
| Cash conversion cycle | 251 | 168 | 263 | 186 | 237 | 193 |
| Working capital days | 112 | 61 | 113 | 97 | 140 | 106 |
| ROCE % | — | 15.1% | 1.0% | −2.0% | 4.0% | 9.1% |
For the Jun 2026 quarter, Makers Laboratories reported sales of ₹42.72 Cr, up 22.2% year on year and net profit of ₹4.60 Cr, up 253.8% year on year. The operating margin was 16.3%.
Makers Laboratories' sales for the year to Mar 2026 were ₹141 Cr; over the last twelve months they were ₹148 Cr.
Net profit for the year to Mar 2026 was ₹8.01 Cr, and ₹11.20 Cr over the last twelve months. Earnings per share over the same trailing period were ₹5.76.
Makers Laboratories reported borrowings of ₹8.97 Cr at Mar 2026, against cash and equivalents of ₹0.64 Cr.
Cash from operations was ₹13.99 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹11.04 Cr.